Xiansheng Pharmaceutical (02096) is pleased to see revenue of 4.55 billion yuan to 4.61 billion yuan in the first half of the year increase of about 26.9% to 28.6% year-on-year

According to Zhitong Finance App, Xiansheng Pharmaceutical (02096) announced that the Group is expected to obtain revenue of approximately RMB 4.55 billion to RMB 4.61 billion in the first half of 2026, an increase of about 26.9% to 28.6% compared with revenue of approximately RMB 3,585 billion for the six months ended June 30, 2025 (first half of 2025).

The Group is expected to obtain profits attributable to the Company's equity shareholders of approximately RMB 810 million to RMB 860 million in the first half of 2026, an increase of about 34.8% to 43.1% compared with the restated profit attributable to equity shareholders of the Company of approximately RMB 601 million in the first half of 2025. The Group obtained adjusted profit attributable to shareholders of the Company in the first half of 2026 of approximately RMB 950 million to RMB 1.0 billion, an increase of approximately 46.5% to 54.2% compared to the adjusted profit attributable to shareholders of the Company of RMB 649 million in the first half of 2025. The increase in the aforementioned indicators is mainly due to an increase in revenue from innovative drugs and external licensing revenue.